Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. Interested parties can access both the live webcast and archived replay of the presentation through the "Events and Presentations" section of Zenas BioPharma's website under Investor & Media Relations.
Zenas BioPharma (Nasdaq: ZBIO), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie autoimmuni, ha annunciato la sua prossima partecipazione alla Jefferies Global Healthcare Conference. Il management dell'azienda terrà una presentazione giovedì 5 giugno 2025 alle 13:25 ET. Gli interessati potranno seguire sia la diretta streaming sia la registrazione della presentazione nella sezione "Eventi e Presentazioni" del sito web di Zenas BioPharma, nella sezione Investor & Media Relations.
Zenas BioPharma (Nasdaq: ZBIO), una compañía biofarmacéutica en etapa clínica centrada en terapias para enfermedades autoinmunes, ha anunciado su próxima participación en la Jefferies Global Healthcare Conference. La dirección de la empresa realizará una presentación el jueves 5 de junio de 2025 a la 1:25 p.m. ET. Las personas interesadas podrán acceder tanto a la transmisión en vivo como a la repetición archivada de la presentación a través de la sección "Eventos y Presentaciones" en el sitio web de Zenas BioPharma, bajo Relaciones con Inversores y Medios.
Zenas BioPharma (나스닥: ZBIO)는 자가면역 질환 치료제에 중점을 둔 임상 단계의 바이오제약 회사로, Jefferies Global Healthcare Conference에 곧 참가할 예정임을 발표했습니다. 회사 경영진은 2025년 6월 5일 목요일 오후 1시 25분(동부 시간)에 발표를 진행할 예정입니다. 관심 있는 분들은 Zenas BioPharma 웹사이트의 투자자 및 미디어 관계 섹션 내 "이벤트 및 발표"에서 생중계 및 녹화된 발표를 시청할 수 있습니다.
Zenas BioPharma (Nasdaq : ZBIO), une société biopharmaceutique en phase clinique spécialisée dans les thérapies des maladies auto-immunes, a annoncé sa prochaine participation à la Jefferies Global Healthcare Conference. La direction de l'entreprise présentera le jeudi 5 juin 2025 à 13h25 ET. Les intéressés pourront accéder à la fois au webcast en direct et à la rediffusion de la présentation via la section "Événements et Présentations" du site web de Zenas BioPharma, dans la rubrique Relations avec les investisseurs et les médias.
Zenas BioPharma (Nasdaq: ZBIO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Therapien für Autoimmunerkrankungen, hat seine bevorstehende Teilnahme an der Jefferies Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 13:25 Uhr ET eine Präsentation halten. Interessierte können sowohl das Live-Webcast als auch die archivierte Wiedergabe der Präsentation über den Bereich "Events and Presentations" auf der Website von Zenas BioPharma unter Investor & Media Relations abrufen.
- None.
- None.
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.
A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
FAQ
When is Zenas BioPharma (ZBIO) presenting at the Jefferies Global Healthcare Conference 2025?
How can I watch Zenas BioPharma's (ZBIO) presentation at the Jefferies Healthcare Conference?
What is Zenas BioPharma's (ZBIO) main business focus?
What stock exchange is Zenas BioPharma (ZBIO) listed on?
